VJOncology is committed to improving our service to you

ESMO 2019 | Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma

VJOncology is committed to improving our service to you

Paolo Ascierto

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, presents the results of the phase 3 CheckMate 238 trial (NCT02388906), which looked at adjuvant nivolumab vs. ipilimumab in resected stage III/IV melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter